CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. However, only a portion of patients respond to such treatments. Therefore, it remains a prevailing clinical need to identify factors associated with acquired resistance or lack of response to ICIs. We hypoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozorgmehr, Najmeh, Okoye, Isobel, Mashhouri, Siavash, Lu, Julia, Koleva, Petya, Walker, John, Elahi, Shokrollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230995/
https://www.ncbi.nlm.nih.gov/pubmed/37236637
http://dx.doi.org/10.1136/jitc-2022-006595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230995/
https://www.ncbi.nlm.nih.gov/pubmed/37236637
http://dx.doi.org/10.1136/jitc-2022-006595

Ejemplares similares